Top

BMC Complementary Medicine and Therapies

Published in:

01-12-2021 | Rheumatoid Arthritis | Research article

Bioactive fractions and compound of Ardisia crispa roots exhibit anti-arthritic properties mediated via angiogenesis inhibition in vitro

Authors: Joan Anak Blin, Roslida Abdul Hamid, Huzwah Khaza’ai

Published in: BMC Complementary Medicine and Therapies | Issue 1/2021

Abstract

Background

Ardisia crispa (Thunb.) A.DC (Primulaceae), is a medicinal herb traditionally used by Asian people as remedies to cure inflammatory related diseases, including rheumatism. The plant roots possess various pharmacological activities including antipyretic, anti-inflammation and antitumor. Previous phytochemical studies of the plant roots have identified long chain alkyl-1,4-benzoquinones as major constituents, together with other phytochemicals. Hexane fraction of the plant roots (ACRH), was previously reported with anti-angiogenic and anti-arthritic properties, while its effect on their anti-arthritic in vitro, is yet unrevealed. Considering the significance of angiogenesis inhibition in developing new anti-arthritic agent, thus we investigated the anti-arthritic potential of Ardisia crispa roots by suppressing angiogenesis, in vitro.

Methods

Ardisia crispa roots hexane extract (ACRH) was prepared from the plant roots using absolute n-hexane. ACRH was fractionated into quinone-rich fraction (QRF) and further isolated to yield benzoquinonoid compound (BQ), respectively. In vitro experiments using VEGF-induced human umbilical vein endothelial cells (HUVECs) and IL-1β-induced human fibroblast-like synoviocytes for rheumatoid arthritis (HFLS-RA) were performed to evaluate the effects of these samples on VEGF-induced HUVECs proliferation and tube formation, and towards IL-1β-induced HFLS-RA proliferation, invasion, and apoptosis, respectively. Therapeutic concentrations (0.05, 0.5, and 5 μg/mL) tested in this study were predetermined based on the IC₅₀ values obtained from the MTT assay.

Results

ACRH, QRF, and BQ exerted concentration-independent antiproliferative effects on VEGF-induced HUVECs and IL-1β-induced HFLS-RA, with IC₅₀ values at 1.09 ± 0.18, 3.85 ± 0.26, and 1.34 ± 0.16 μg/mL in HUVECs; and 3.60 ± 1.38, 4.47 ± 0.34, and 1.09 ± 0.09 μg/mL in HFLS-RA, respectively. Anti-angiogenic properties of these samples were verified via significant inhibition on VEGF-induced HUVECs tube formation, in a concentration-independent manner. The invasiveness of IL-1β-induced HFLS-RA was also significantly inhibited in a concentration-independent manner by all samples. ACRH and BQ, but not QRF, significantly enhanced the apoptosis of IL-1β-induced HFLS-RA elicited at their highest concentration (5 μg/mL) (P < 0.05).

Conclusions

These findings highlight the bioactive fractions and compound from Ardisia crispa roots as potential anti-arthritic agents by inhibiting both HUVECs and HFLS-RA’s cellular functions in vitro, possibly mediated via their anti-angiogenic effects.

Available only for authorised users

Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–38. https://doi.org/10.1016/s0140-6736(16)30173-8.CrossRefPubMed

Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2016;68(1):1–25. https://doi.org/10.1002/acr.22783.CrossRef

Henrique da Mota LM, Afonso Cruz B, Viegas Brenol C, Alves Pereira I, Rezende-Fronza LS, Barros Bertolo M, et al. Guidelines for the drug treatment of rheumatoid arthritis. Rev Bras Reumatol. 2013;53(2):158–83. https://doi.org/10.1590/S0482-50042013000200004.CrossRef

Xiang G, Jinyu J, Zhitao F, Xiaoqiang H, Yanan L, Zhigang M. A network pharmacology approach to explore the potential targets underlying the effect of sinomenine on rheumatoid arthritis. Int Immunopharmacol. 2020;80(106201). https://doi.org/10.1016/j.intimp.2020.106201.

Tarp S, Furst DE, Boers M, Luta G, Bliddal H, Tarp U, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. Rheumatology (Oxford). 2017;56(3):417–25. https://doi.org/10.1093/rheumatology/kew442.CrossRef

Szekanecz Z, Koch AE. Angiogenesis and its targeting in rheumatoid arthritis. Vasc Pharmacol. 2009;51(1):1–7. https://doi.org/10.1016/j.vph.2009.02.002.CrossRef

Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438(7070):932–6. https://doi.org/10.1038/nature04478.CrossRefPubMed

Volin MV, Koch AE. Interleukin-18: a mediator of inflammation and angiogenesis in rheumatoid arthritis. J Interf Cytokine Res. 2011;31(10):745–51. https://doi.org/10.1089/jir.2011.0050.CrossRef

Leblond A, Allanore Y, Avouac J. Targeting synovial neoangiogenesis in rheumatoid arthritis. Autoimmun Rev. 2017;16(6):594–601. https://doi.org/10.1016/j.autrev.2017.04.005.CrossRefPubMed

10.

Liu S, Li Y, Xia L, Shen H, Lu J. IL-35 prevent bone loss through promotion of bone formation and angiogenesis in rheumatoid arthritis. Clin Exp Rheumatol. 2019;37(5):820–5.PubMed

11.

Magro R. Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus. Therapeutic Adv Musculoskeletal Dis. 2019;11:1–9. https://doi.org/10.1177/1759720x19874309.CrossRef

12.

Šenolt L, Vencovský J, Pavelka K, Ospelt C, Gay S. Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev. 2009;9(2):102–7. https://doi.org/10.1016/j.autrev.2009.03.010.CrossRefPubMed

13.

Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological therapies in immune-mediated inflammatory diseases: Can biosimilars reduce access inequities? Frontiers in Pharmacology. 2019;10(279). https://doi.org/10.3389/fphar.2019.00279.

14.

Moudgil KD, Berman BM. Traditional Chinese medicine: potential for clinical treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2014;10(7):819–22. https://doi.org/10.1586/1744666x.2014.917963.CrossRefPubMedPubMedCentral

15.

Tabana YM, Al-Suede FSR, Ahamed MBK, et al. Cat’s whiskers (Orthosiphon stamineus) tea modulates arthritis pathogenesis via the angiogenesis and inflammatory cascade. BMC Complement Altern Med. 2016;16(1):480. https://doi.org/10.1186/s12906-016-1467-4.CrossRefPubMedPubMedCentral

16.

Song X, Zhang Y, Dai E, Wang L, Du H. Prediction of triptolide targets in rheumatoid arthritis using network pharmacology and molecular docking. Int Immunopharmacol. 2020;80:106179. https://doi.org/10.1016/j.intimp.2019.106179.CrossRefPubMed

17.

Nimesh S. Herbal drug is better than allopathic drug in the treatment of rheumatoid arthritis. Int J Pharm. 2018;5(9):539–45. https://doi.org/10.13040/IJPSR.0975-8232.IJP.CrossRef

18.

Avendaño C, Menéndez JC. Drug targeting in anticancer chemotherapy. Med Chem Anticancer Drugs. 2015:595–653. https://doi.org/10.1016/b978-0-444-62649-3.00013-2.

19.

Velderrain-Rodríguez GR, Palafox-Carlos H, Wall-Medrano A, Ayala-Zavala JF, Chen CYO, Robles-Sánchez M, et al. Phenolic compounds: their journey after intake. Food Funct. 2014;5(2):189–97. https://doi.org/10.1039/c3fo60361j.CrossRefPubMed

20.

Lin D, Xiao M, Zhao J, Li Z, Xing B, Li X, et al. An overview of plant phenolic compounds and their importance in human nutrition and management of type 2 diabetes. Molecules. 2016;21(10):1374. https://doi.org/10.3390/molecules21101374.CrossRefPubMedCentral

21.

De Mejía EG, Ramírez-Mares MV. Ardisia: health-promoting properties and toxicity of phytochemicals and extracts. Toxicol Mech Methods. 2011;21(9):667–74. https://doi.org/10.3109/15376516.2011.601355.CrossRefPubMed

22.

Nordin ML, Abdul Kadir A, Zakaria ZA, Abdullah R, Abdullah MNH. In vitro investigation of cytotoxic and antioxidative activities of Ardisia crispa against breast cancer cell lines, MCF-7 and MDA-MB-231. BMC Complement Altern Med. 2018;18(1):87. https://doi.org/10.1186/s12906-018-2153-5.CrossRefPubMedPubMedCentral

23.

Perry LM, Metzger J. Medicinal Plants of East and Southeast Asia: Attributed Properties and Uses. Cambridge: MIT Press; 1980. p. 620.

24.

Chaweewan J, Baumann H, Kenne L, Samuelsson G. Ardisiacrispin a and B, two utero-contracting saponins from Ardisia crispa. Planta Med. 1987;53(05):405–9. https://doi.org/10.1055/s-2006-962758.CrossRef

25.

Muhammad Z, Mustafa AM. Traditional Malay medicinal plants. Kuala Lumpur: Fajar Bakti; 1994. p. 39–41.

26.

Kang YH, Kim WH, Park MK, Han BH. Antimetastatic and antitumor effects of benzoquinonoid AC7-1 from Ardisia crispa. Int J Cancer. 2001;93(5):736–40. https://doi.org/10.1002/ijc.1384.CrossRefPubMed

27.

Huang W. Studies on the antitumor active constituents isolated from the root of Ardisia crispa. Master dissertation, Central South University, China. 2007.

28.

Lau MF, Hamid RA, Sabrina S, Nhareet SM. Anti-inflammatory and anti-pyretic effects of hexane fraction of Ardisia crispa Thunb.D.C. Pharmacologyonline. 2009;3:29–39.

29.

Kobayashi H, de Mejía E. The genus Ardisia: a novel source of health-promoting compounds and phytopharmaceuticals. J Ethnopharmacol. 2005;96(3):347–54. https://doi.org/10.1016/j.jep.2004.09.037.CrossRefPubMed

30.

Roslida AH, Kim KH. Anti-inflammatory and anti-hyperalgesic effects of Ardisia crispa Thunb D.C. Pharmacogn Mag. 2008;4:262–8.

31.

Yeong LT, Hamid RA, Yazan LS, Khaza’ai H. Isolation of a Quinone-rich fraction from Ardisia crispa roots and its attenuating effects on murine skin tumorigenesis. Asian Pacific J Cancer Prev. 2013;14(4):2301–5. https://doi.org/10.7314/APJCP.2013.14.4.2301.CrossRef

32.

Hamsin DEZA, Hamid RA, Yazan LS, Taib CNM, Ting YL. The hexane fraction of Ardisia crispa Thunb. A DC roots inhibits inflammation-induced angiogenesis. BMC Complement Altern Med. 2013;13(1):5. https://doi.org/10.1186/1472-6882-13-5.CrossRefPubMedPubMedCentral

33.

Wen Jun L, Foong CP, Hamid RA. Ardisia crispa root hexane fraction suppressed angiogenesis in human umbilical vein endothelial cells (HUVECs) and in vivo zebrafish embryo model. Biomed Pharmacother. 2019;118:109221. https://doi.org/10.1016/j.biopha.2019.109221.CrossRefPubMed

34.

Hamid RA, Fong LM, Ting YL. Anti-arthritic and gastroprotective activities of Ardisia crispa root partially mediated via its antioxidant effect. J Complement Integr Med. 2017;15(1). https://doi.org/10.1515/jcim-2017-0012.

35.

Yeong LT, Hamid RA, Yazan LS, Khaza’ai H, Awang Hamsin DEZ. Synergistic action of compounds isolated from the hexane extract of Ardisia crispa root against tumour-promoting effect in vitro. Nat Prod Res. 2014;28(22):2026–30. https://doi.org/10.1080/14786419.2014.917415.CrossRefPubMed

36.

Roslida AH. Anti-inflammatory and analgesic effects of AC-2 isolated from Ardisia crispa are mediated via COX-2 inhibition. Doctoral dissertation, Universiti Malaya, Malaysia. 2004.

37.

Kong X, Zhang Y, Liu C, Guo W, Li X, Su X, et al. Anti-angiogenic effect of Triptolide in rheumatoid arthritis by targeting angiogenic cascade. PLoS One. 2013;8(10):e77513. https://doi.org/10.1371/journal.pone.0077513.CrossRefPubMedPubMedCentral

38.

Deng Q, Bai S, Gao W, Tong L. Pristimerin inhibits angiogenesis in adjuvant-induced arthritic rats by suppressing VEGFR2 signaling pathways. Int Immunopharmacol. 2015;29(2):302–13. https://doi.org/10.1016/j.intimp.2015.11.001.CrossRefPubMed

39.

Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1-2):55–63. https://doi.org/10.1016/0022-1759(83)90303-4.CrossRefPubMed

40.

Burton JD. The MTT assay to evaluate chemosensitivity. Methods Mol Med. 2005;110:69–78. https://doi.org/10.1385/1-59259-869-2:069.CrossRefPubMed

41.

Wang YJ, Jiao T, Fu WY, Zhao S, Yang LL, Xu NL, et al. miR-410-3p regulates proliferation and apoptosis of fibroblast-like synoviocytes by targeting YY1 in rheumatoid arthritis. Biomed Pharmacother. 2019;119:109426. https://doi.org/10.1016/j.biopha.2019.109426.CrossRefPubMed

42.

Lim WJ. Antiangiogenic effect of Ardisia crispa root hexane extract mediated via its angiogenic signaling cascades. Master dissertation, Universiti Putra Malaysia, Malaysia. 2017.

43.

Bhupinder K, Reena G, Gupta M. Natural products in treatment of rheumatoid arthritis. Int J Green Pharm. 2017;11(3):S356. https://doi.org/10.22377/ijgp.v11i03.1142.CrossRef

44.

El-Ghazaly MA, Fadel NA, Abdel-Naby DH, Abd El-Rehim HA, Zaki HF, Kenawy SA. Potential anti-inflammatory action of resveratrol and piperine in adjuvant-induced arthritis: effect on pro-inflammatory cytokines and oxidative stress biomarkers. Egyptian Rheumatol. 2020;42(1):71–7. https://doi.org/10.1016/j.ejr.2019.08.003.CrossRef

45.

Aguilar-Cazares D, Chavez-Dominguez R, Carlos-Reyes A, Lopez-Camarillo C, de la Cruz ON H, Lopez-Gonzalez JS. Contribution of Angiogenesis to Inflammation and Cancer. Front Oncol. 2019;9:1399. https://doi.org/10.3389/fonc.2019.01399.CrossRefPubMedPubMedCentral

46.

Tas S, Maracle C, Balogh E, Szekanecz Z. Targeting of pro-angiogenic signalling pathways in chronic inflammation. Nat Rev Rheumatol. 2016;12(2):111–22. https://doi.org/10.1038/nrrheum.2015.164.CrossRefPubMed

47.

Awang Hamsin DEZ, Hamid AR, Yazan SL, Taib CNM, Yeong LT. Ardisia crispa roots inhibit cyclooxygenase and suppress angiogenesis. BMC Complement Altern Med. 2014;14(1):102. https://doi.org/10.1186/1472-6882-14-102.CrossRefPubMedCentral

48.

Saranadasa M, Wang ES. Vascular endothelial growth factor inhibition: conflicting roles in tumor growth. Cytokine. 2011;53(2):115–29. https://doi.org/10.1016/j.cyto.2010.06.012.CrossRefPubMed

49.

Gutierrez PL. The metabolism of quinone-containing alkylating agents: free radical production and measurement. Front Biosci. 2000;5:d629–38. https://doi.org/10.2741/gutier.CrossRefPubMed

50.

Saibu M, Sagar S, Green I, Ameer F, Meyer M. Evaluating the cytotoxic effects of novel quinone compounds. Anticancer Res. 2014;34(8):4077–86.PubMed

51.

Acharya BR, Chatterjee A, Ganguli A, Bhattacharya S, Chakrabarti G. Thymoquinone inhibits microtubule polymerization by tubulin binding and causes mitotic arrest following apoptosis in A549 cells. Biochimie. 2014;97:78e91. https://doi.org/10.1016/j.biochi.2013.09.025.CrossRef

52.

Pap T, Dankbar B, Wehmeyer C, Korb-Pap A, Sherwood J. Synovial fibroblasts and articular tissue remodelling: role and mechanisms. Semin Cell Dev Biol. 2020;101:140–5. https://doi.org/10.1016/j.semcdb.2019.12.006.CrossRefPubMed

53.

Clarimundo VS, Farinon M, Pedó RT, Teixeira VON, Nör C, Gulko PS, et al. Gastrin-releasing peptide and its receptor increase arthritis fibroblast-like synoviocytes invasiveness through activating the PI3K/AKT pathway. Peptides. 2017;95:57–61. https://doi.org/10.1016/j.peptides.2017.07.008.CrossRefPubMed

54.

Bustamante MF, Garcia-Carbonell R, Whisenant KD, Guma M. Fibroblast-like synoviocytes metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):110. https://doi.org/10.1186/s13075-017-1303-3.CrossRefPubMedPubMedCentral

55.

Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010;233(1):233–55. https://doi.org/10.1111/j.0105-2896.2009.00859.x.CrossRefPubMedPubMedCentral

56.

Ganesan R, Rasool M. Fibroblast-like synoviocytes-dependent effector molecules as a critical mediator for rheumatoid arthritis: current status and future directions. Int Rev Immunol. 2017;36(1):20–30. https://doi.org/10.1080/08830185.2016.1269175.CrossRefPubMed

57.

Xing L, Yang Y, Jin L, Sun C, Li Z, Li J, et al. Interleukin-21 induces proliferation and proinflammatory cytokine profile of fibroblast-like synoviocytes of patients with rheumatoid arthritis. Scand J Immunol. 2016;83(1):64–71. https://doi.org/10.1111/sji.12396.CrossRefPubMed

58.

Firestein GS. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol. 2005;11(3):39–44. https://doi.org/10.1097/01.rhu.0000166673.34461.33.CrossRef

59.

Scian R, Barrionuevo P, Giambartolomei GH, De Simone EA, Vanzulli SI, Fossati CA, et al. Potential role of fibroblast-like synoviocytes in joint damage induced by Brucella abortus infection through production and induction of matrix metalloproteinases. Infect Immun. 2011;79(9):3619–32. https://doi.org/10.1128/IAI.05408-11.CrossRefPubMedPubMedCentral

60.

Lee A, Choi SJ, Park K, Park JW, Kim K, Choi K, et al. Detection of active matrix metalloproteinase-3 in serum and fibroblast-like synoviocytes of collagen-induced arthritis mice. Bioconjug Chem. 2013;24(6):1068–74. https://doi.org/10.1021/bc4001273.CrossRefPubMed

61.

Kima KW, Choa ML, Lee SH, Oha HJ, Kanga CM, Ju JH, et al. Human rheumatoid synovial fibroblasts promote osteoclastogenic activity by activating RANKL via TLR-2 and TLR-4 activation. Immunol Lett. 2007;110(1):54–64. https://doi.org/10.1016/j.imlet.2007.03.004.CrossRef

62.

Yamanishi Y, Firestein GS. Pathogenesis of rheumatoid arthritis: the role of synoviocytes. Rheum Dis Clin N Am. 2001;27(2):355–71. https://doi.org/10.1016/s0889-857x(05)70206-4.CrossRef

63.

Jeoung B, Lee KD, Na C, et al. Ganghwaljetongyeum, an anti-arthritic remedy, attenuates synoviocyte proliferation and reduces the production of proinflammatory mediators in macrophages: the therapeutic effect of GHJTY on rheumatoid arthritis. BMC Complement Altern Med. 2013;13(1):13–47. https://doi.org/10.1186/1472-6882-13-47.CrossRef

64.

Yao Y, Jiang C-S, Sun N, Li W-Q, Niu Y, Han H-Q, et al. Tamaractam, a new bioactive lactam from Tamarix ramosissima, induces apoptosis in rheumatoid arthritis fibroblast-like synoviocytes. Molecules. 2017;22(1):96. https://doi.org/10.3390/molecules22010096.CrossRefPubMedCentral

65.

Li G, Liu D, Guo S, Sunagawa M, Hisamitsu T, Liu Y. Anti-invasive effects of Celastrus Orbiculatus extract on interleukin-1 beta and tumour necrosis factor-alpha combination-stimulated fibroblast-like synoviocytes. BMC Complement Altern Med. 2014;14(1):62. https://doi.org/10.1186/1472-6882-14-62.CrossRefPubMedPubMedCentral

66.

Sun HN, Luo YH, Meng LQ, Piao XJ, Wang Y, Wang JR, et al. Cryptotanshinone induces reactive oxygen species-mediated apoptosis in human rheumatoid arthritis fibroblast-like synoviocytes. Int J Mol Med. 2019;43:1067–75. https://doi.org/10.3892/ijmm.2018.4012.CrossRefPubMed

67.

Umar S, Hedaya O, Singh HA, Ahmed S. Thymoquinone inhibits TNF-α-induced inflammation and cell adhesion in rheumatoid arthritis synovial fibroblasts by ASK1 regulation. Toxicol Appl Pharmacol. 2015;287(3):299–305. https://doi.org/10.1016/j.taap.2015.06.017.CrossRefPubMedPubMedCentral

68.

Nordin ML, Abdul Kadir A, Zakaria ZA, Othman F, Abdullah R, Abdullah MNH. Cytotoxicity and apoptosis induction of Ardisia crispa and its solvent partitions against Mus musculus mammary carcinoma cell line (4T1). Evid Based Complement Alternat Med. 2017;2017:1–10. https://doi.org/10.1155/2017/9368079.CrossRef

69.

Liu FF, Chen CH, Chu SJ, Chen JH, Lai JH, Sytwu HK, et al. Interleukin (IL)-23 p19 expression induced by IL-1b in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor-κB and AP-1 dependent pathway. Rheumatology. 2007;46(8):1266–73. https://doi.org/10.1093/rheumatology/kem055.CrossRefPubMed

70.

Zhang Q, Liu J, Zhang M, Wei S, Gao Y, Peng W, et al. Apoptosis induction of fibroblast-like synoviocytes is an important molecular-mechanism for herbal medicine along with its active components in treating rheumatoid arthritis. Biomolecules. 2019;9(12):795. https://doi.org/10.3390/biom9120795.CrossRefPubMedCentral

71.

Middleton J, Americh L, Gayon R, Julien D, Aguilar L, Amalric F, et al. Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky. Arthritis Res Ther. 2004;6(2):60–72. https://doi.org/10.1186/ar1156.CrossRefPubMedPubMedCentral

72.

Yeong LT, Hamid RA, Yazan LS, Huzwah Khaza’ai H, Mohtarrudin M. Low dose triterpene-quinone fraction from Ardisia crispa root precludes chemical-induced mouse skin tumor promotion. BMC Complement Altern Med. 2015;15(1):431. https://doi.org/10.1186/s12906-015-0954-3.CrossRefPubMedPubMedCentral

73.

Malemud CJ. The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis? Future Med Chem. 2015;7(9):1137–47. https://doi.org/10.4155/fmc.15.55.CrossRefPubMed

74.

Draoui N, de Zeeuw P, Carmeliet P. Angiogenesis revisited from a metabolic perspective: role and therapeutic implications of endothelial cell metabolism. Open Biol. 2017;7(12):170219. https://doi.org/10.1098/rsob.170219.CrossRefPubMedPubMedCentral

75.

Cantatore FP, Maruotti N, Corrado A, Ribatti D. Anti-angiogenic effects of biotechnological therapies in rheumatic diseases. Biologics: Targets and Therapy. 2017;11:123–8. https://doi.org/10.2147/btt.s143674.CrossRef

76.

Gibbons LJ, Hyrich KL. Biologic therapy for rheumatoid arthritis. BioDrugs. 2009;23(2):111–24. https://doi.org/10.2165/00063030-200923020-00004.CrossRefPubMed

77.

Pascual-Salcedo D, Plasencia C, Ramiro S, Nuno L, Bonilla G, Nagore D, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology. 2011;50(8):1445–52. https://doi.org/10.1093/rheumatology/ker124.CrossRefPubMed

78.

Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117(14):3720–32. https://doi.org/10.1182/blood-2010-07-273417.CrossRefPubMedPubMedCentral

79.

Hirohata S, Abe A, Murasawa A, Kanamono T, Tomita T, Yoshikawa H. Differential effects of IL-6 blockade tocilizumab and TNF inhibitors on angiogenesis in synovial tissues from patients with rheumatoid arthritis. Mod Rheumatol. 2016;27(5):766–72. https://doi.org/10.1080/14397595.2016.1259717.CrossRefPubMed

80.

Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther. 2011;33(6):679–707. https://doi.org/10.1016/j.clinthera.2011.05.044.CrossRefPubMedPubMedCentral

81.

Balsa A, Tovar Beltrán JV, Cáliz Cáliz R, et al. Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study. Rheumatol Int. 2015;35(9):1525–34. https://doi.org/10.1007/s00296-015-3237-x.CrossRefPubMed

82.

Wadström H, Frisell T, Askling J. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, Abatacept, or rituximab in clinical practice. JAMA Intern Med. 2017;177(11):1605–12. https://doi.org/10.1001/jamainternmed.2017.4332.CrossRefPubMedPubMedCentral

83.

Laragione T, Gulko PS. mTOR regulates the invasive properties of synovial fibroblasts in rheumatoid arthritis. Mol Med. 2010;16(9–10):352–8. https://doi.org/10.2119/molmed.2010.00049.CrossRefPubMedPubMedCentral

84.

Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Phys Cell Phys. 2002;282(5):C947–70. https://doi.org/10.1152/ajpcell.00389.2001.CrossRef

85.

Wang Y, Xu J, Zhang X, Wang C, Huang Y, Dai K, et al. TNF-α-induced LRG1 promotes angiogenesis and mesenchymal stem cell migration in the subchondral bone during osteoarthritis. Cell Death Dis. 2017;8(3):e2715. https://doi.org/10.1038/cddis.2017.129.CrossRefPubMedPubMedCentral

86.

Ushio-Fukai M. Redox signaling in angiogenesis: role of NADPH oxidase. Cardiovasc Res. 2006;71(2):226–35. https://doi.org/10.1016/j.cardiores.2006.04.015.CrossRefPubMed

Title: Bioactive fractions and compound of Ardisia crispa roots exhibit anti-arthritic properties mediated via angiogenesis inhibition in vitro
Authors: Joan Anak Blin
Roslida Abdul Hamid
Huzwah Khaza’ai
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Rheumatoid Arthritis
Published in: BMC Complementary Medicine and Therapies / Issue 1/2021
Electronic ISSN: 2662-7671
DOI: https://doi.org/10.1186/s12906-021-03341-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Bioactive fractions and compound of Ardisia crispa roots exhibit anti-arthritic properties mediated via angiogenesis inhibition in vitro

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Protective effects of exosomes derived from lyophilized porcine liver against acetaminophen damage on HepG2 cells

Antitumor effect and molecular mechanism of fucoidan in NSCLC

Phytochemical analysis, in-vitro anti-proliferative, anti-oxidant, anti-diabetic, and anti-obesity activities of Rumex rothschildianus Aarons. extracts

Eye acupuncture for pain conditions: a scoping review of clinical studies

The beneficial effects of the composite probiotics from camel milk on glucose and lipid metabolism, liver and renal function and gut microbiota in db/db mice

Neuroprotective effects of pomegranate (Punica granatum L.) juice and seed extract in paraquat-induced mouse model of Parkinson’s disease